Halozyme Therapeutics Inc (HALO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The companys marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. Its products are based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc (HALO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Licensing Agreements 13
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Equity Offering 20
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For US$115 Million 22
Halozyme Completes Public Offering Of Common Stock For US$83 Million 23
Halozyme Therapeutics Inc - Key Competitors 25
Halozyme Therapeutics Inc - Key Employees 26
Halozyme Therapeutics Inc - Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 06, 2018: Halozyme reports third quarter 2018 financial results 28
Aug 08, 2018: Halozyme reports second quarter 2018 results 30
May 10, 2018: Halozyme Reports First Quarter 2018 Results 31
Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 32
Nov 07, 2017: Halozyme Reports Third Quarter 2017 Results 33
Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 35
May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 36
Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2018: Halozyme appoints Benjamin Hickey as Chief Commercial Officer 39
Product News 40
11/10/2017: Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors 40
10/24/2017: First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozymes PEGPH20 In Combination With Anti-PDL1 Immunotherapy 41
10/16/2017: Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients 42
07/13/2017: Initiation Of Clinical Trial Collaboration Evaluating Halozymes PEGPH20 In Combination With Anti-PDL1 Immunotherapy 43
06/04/2017: Experimental drug makes some pancreatic cancers more vulnerable to chemo 44
05/31/2017: Clinical trial shows experimental drugs ability to knock down pancreatic cancers defense 46
03/30/2017: Halozyme Provides Update On SWOG Collaborative Group Clinical Study 48
01/09/2017: Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference 49
Clinical Trials 50
Jun 28, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium 50
Jun 04, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO 52
May 17, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO 54
Apr 03, 2017: Halozymes PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models 56
Jan 05, 2017: Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints 58
Other Significant Developments 59
Jan 09, 2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List Of Tables


Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For US$115 Million 22
Halozyme Completes Public Offering Of Common Stock For US$83 Million 23
Halozyme Therapeutics Inc, Key Competitors 25
Halozyme Therapeutics Inc, Key Employees 26
Halozyme Therapeutics Inc, Subsidiaries 27

List Of Figures


Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Halozyme Therapeutics Inc (HALO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The companys

USD 250 View Report

Halozyme Therapeutics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Halozyme Therapeutics Inc Company Profile is a detailed strategic and analytical report on Halozyme Therapeutics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Anika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2019 Update

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products

USD 750 View Report

Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD)

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available